MEI Pharma, Kyowa Kirin Highlight Updated Clinical Data From Phase 1b Study Of ME-401 On Intermittent Schedule in Patients with Follicular Lymphoma and Other B-cell Malignancies For ASCO: 83% Overall Response Rate